Whetstone Capital Advisors LLC purchased a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,350,423 shares of the company's stock, valued at approximately $6,563,000. OptimizeRx comprises about 2.1% of Whetstone Capital Advisors LLC's investment portfolio, making the stock its 17th largest position. Whetstone Capital Advisors LLC owned 7.33% of OptimizeRx as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new position in shares of OptimizeRx in the 4th quarter valued at $25,000. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx during the fourth quarter worth about $51,000. Wells Fargo & Company MN lifted its holdings in shares of OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after purchasing an additional 21,060 shares during the period. Institutional investors and hedge funds own 76.47% of the company's stock.
Insider Buying and Selling at OptimizeRx
In other news, Director James Paul Lang bought 321,408 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.10% of the stock is owned by insiders.
OptimizeRx Price Performance
Shares of NASDAQ OPRX traded down $0.36 on Wednesday, hitting $7.97. The company's stock had a trading volume of 36,787 shares, compared to its average volume of 471,212. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. OptimizeRx Co. has a 12-month low of $3.78 and a 12-month high of $14.13. The company has a market capitalization of $147.37 million, a price-to-earnings ratio of -5.99 and a beta of 1.18. The stock has a 50 day moving average of $6.97 and a 200-day moving average of $6.03.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. JMP Securities reiterated a "market outperform" rating and issued a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Lake Street Capital reiterated a "buy" rating and set a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley upgraded shares of OptimizeRx to a "strong-buy" rating in a research note on Wednesday, March 12th. Finally, Stephens assumed coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.50 target price for the company. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, OptimizeRx has a consensus rating of "Moderate Buy" and an average price target of $9.06.
Check Out Our Latest Research Report on OptimizeRx
OptimizeRx Company Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
See Also
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
